In a clinical trial that compared it tohaloperidol in the treatment of schizophrenia it was found to produce significantly superior overall symptom control.[5] In another clinical trial perospirone was compared withmosapramine and produced a similar reduction in totalPANSS score, except with respect to the blunted affect part of the PANSS negative score, in which perospirone produced a significantly greater improvement.[6] In an open-label clinical trial comparingaripiprazole with perospirone there was no significant difference between the two treatments discovered in terms of both efficacy and tolerability.[7] In 2009 a clinical trial found that perospirone produced a similar reduction of PANSS score thanrisperidone and the extrapyramidal side effects was similar in both frequency and severity between groups.[8]
A meta-analysis published in 2013 found that it is statistically significantly less efficacious than other second-generation antipsychotics.[9]
Has a higher incidence of extrapyramidal side effects than the other atypical antipsychotics, but still less than that seen with typical antipsychotics.[1][10] A trend was observed in a clinical trial comparing mosapramine with perospirone that favoured perospirone for producing less prominent extrapyramidal side effects than mosapramine although statistical significant was not reached.[6] It may produce lessQT interval prolongation thanzotepine, as in one patient who had previously been on zotepine switching to perospirone corrected their prolonged QT interval.[11] It also tended to produce less severeextrapyramidal side effects than haloperidol in a clinical trial comparing the two (although statistical significance was not reached).[5]
TheBritish National Formulary recommends a gradual withdrawal when discontinuing antipsychotics to avoid acute withdrawal syndrome or rapid relapse.[12] Symptoms of withdrawal commonly include nausea, vomiting, and loss of appetite.[13] Other symptoms may include restlessness, increased sweating, and trouble sleeping.[13] Less commonly there may be a felling of the world spinning, numbness, or muscle pains.[13] Symptoms generally resolve after a short period of time.[13]
There is tentative evidence that discontinuation of antipsychotics can result in psychosis.[14] It may also result in reoccurrence of the condition that is being treated.[15] Rarely tardive dyskinesia can occur when the medication is stopped.[13]
^Yasui-Furukori N, Furukori H, Nakagami T, Saito M, Inoue Y, Kaneko S, Tateishi T (August 2004). "Steady-state pharmacokinetics of a new antipsychotic agent perospirone and its active metabolite, and its relationship with prolactin response".Therapeutic Drug Monitoring.26 (4):361–365.doi:10.1097/00007691-200408000-00004.PMID15257064.S2CID43362616.
^abde Paulis T (January 2002). "Perospirone (Sumitomo Pharmaceuticals)".Current Opinion in Investigational Drugs.3 (1):121–129.PMID12054062.
^abMurasaki M, Koyama T, Machiyama Y, et al. (1997). "Clinical evaluation of a new antipsychotic, perospirone HCl, on schizophrenia: a comparative double-blind study with haloperidol".Rinsho Hyoka.24 (2–3):159–205.
^abKudo Y, Nakajima T, Saito M, et al. (1997). "Clinical evaluation of a serotonin-2 and dopamine-2 receptor antagonist (SDA), perospirone HCl on schizophrenia: a comparative double-blind study with mosapramine HCl".Rinsho Hyoka.24 (2–3):207–48.
^Takekita Y, Kato M, Wakeno M, Sakai S, Suwa A, Nishida K, et al. (January 2013). "A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients".Progress in Neuro-Psychopharmacology & Biological Psychiatry.40:110–114.doi:10.1016/j.pnpbp.2012.09.010.PMID23022672.S2CID10315774.
^abcdeKishi T, Iwata N (September 2013). "Efficacy and tolerability of perospirone in schizophrenia: a systematic review and meta-analysis of randomized controlled trials".CNS Drugs.27 (9):731–741.doi:10.1007/s40263-013-0085-7.PMID23812802.S2CID11543666.
^"Perospirone Hydrochloride".Martindale: The Complete Drug Reference. The Royal Pharmaceutical Society of Great Britain. 23 September 2011. Retrieved3 November 2013.
^Suzuki Y, Watanabe J, Sugai T, Fukui N, Ono S, Tsuneyama N, et al. (April 2012). "Improvement in QTc prolongation induced by zotepine following a switch to perospirone".Psychiatry and Clinical Neurosciences.66 (3): 244.doi:10.1111/j.1440-1819.2012.02321.x.PMID22443250.S2CID32269750.
^Joint Formulary Committee, BMJ, ed. (March 2009). "4.2.1".British National Formulary (57 ed.). United Kingdom: Royal Pharmaceutical Society of Great Britain. p. 192.ISBN978-0-85369-845-6.Withdrawal of antipsychotic drugs after long-term therapy should always be gradual and closely monitored to avoid the risk of acute withdrawal syndromes or rapid relapse.
^Moncrieff J (July 2006). "Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse".Acta Psychiatrica Scandinavica.114 (1):3–13.doi:10.1111/j.1600-0447.2006.00787.x.PMID16774655.S2CID6267180.
^Roth BL, Driscol, J (12 January 2011)."PDSP Ki Database".Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Archived fromthe original on 8 November 2013. Retrieved3 November 2013.
^Odagaki Y, Toyoshima R (2007). "5-HT1A receptor agonist properties of antipsychotics determined by [35S]GTPgammaS binding in rat hippocampal membranes".Clinical and Experimental Pharmacology & Physiology.34 (5–6):462–466.doi:10.1111/j.1440-1681.2007.04595.x.PMID17439416.S2CID22450517.
^Seeman P, Tallerico T (March 1998). "Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors".Molecular Psychiatry.3 (2):123–134.doi:10.1038/sj.mp.4000336.PMID9577836.S2CID16484752.
N
Y (what is this?) (verify)